Drug Profile
Research programme: autoimmune disease therapy - TransTech Pharma
Alternative Names: Autoimmune disease therapy research programme - TransTech PharmaLatest Information Update: 21 Sep 2010
Price :
$50
*
At a glance
- Originator TransTech Pharma
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders
Most Recent Events
- 21 Sep 2010 Discontinued - Preclinical for Autoimmune disorders in USA (PO)
- 11 Nov 2004 Early research in Autoimmune disorders in USA (PO)